Methods of treating cancer comprising targeting NQO1
Disclosed herein are methods for determining whether an individual with cancer is suitable for a treatment with an NQO1 bioactivatable drug, predicting responsiveness of an individual with cancer to a treatment with an NQO1 bioactivatable drug, and treating an individual with cancer with an NQO1 bioactivatable drug composition.
1. A method of treating an individual having cancer with an NQO1 bioactivatable drug comprising:
(a) measuring the protein or enzymatic level of NQO1 and catalase in cancer cells from the individual;
(b) detecting at least about a 50-fold increased ratio of NQO1:catalase in the cancer cells compared to a NQO1:catalase ratio in corresponding normal tissues; and
(c) administering an NQO1 bioactivatable drug to the individual for cancer treatment.
2. The method of claim 1 , wherein the ratio of the NQO1 level over the catalase level in the cancer cells from the individual is at least about 60-fold or at least about 70-fold of the ratio in a normal tissue.
3. The method of claim 2 , wherein the normal tissue is from the individual.
4. The method of claim 1 , wherein the NQO1 bioactivatable drug is a β-lapachone compound, streptonigrin, or deoxynyboquinone (DNQ).
5. The method of claim 1 , wherein the cancer is lung cancer, prostate cancer, breast cancer, pancreatic cancer, colon cancer or melanoma.
6. The method of claim 1 , wherein the protein level of the NQO1 expression and/or the catalase expression is measured by the enzymatic activity or the amount of the protein in the cancer cells and in the normal tissue from the individual.
7. The method of claim 1 , wherein the individual is a human.
8. The method of claim 1 , wherein the normal tissue is an associated normal tissue.
9. The method of claim 1 , wherein the cancer cells are from a cancer biopsy from the individual or circulating cancer cells from the individual.